| |
Ellen S. Baron, Ph.D.
Partner
Boston, MA
ebaron@oxbio.com |
Dr. Baron joined Oxford Bioscience Partners in 2003 and is currently a Partner at the firm. She has over 20 years of operating and investment expertise in the pharmaceutical and biotechnology industry and is focused on all areas of healthcare investing, principally in biotherapeutics. Her current investments include BrainCells Inc (platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, Claros Diagnostics (diagnostic system delivering quantitative laboratory blood test results with ease-of-use for the point-of-care (POC), Tragara Pharmaceuticals (cancer clinical and commercial development),and VaxInnate Corporation (recombinant vaccine technology for pandemic and seasonal influenza). Dr. Baron acts as a Board Observer to Radius (drug therapies for osteoporosis and women's health) and acted as a board observer to Critical Therapeutics prior to its public listing. Prior to joining Oxford, Dr. Baron was Senior Vice President of Business Development at Human Genome Sciences, Inc. Prior to Human Genome Sciences, Dr. Baron spent 20 years at Schering-Plough Corporation in both Research and Development and Business Development. Dr. Baron received her B.A. from Goucher College, her Ph.D. in Microbiology from Georgetown University School of Medicine and was a post-doctoral at the Public Health Research Institute in New York.
Back to OBP Team
|
|